Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo ...

5 The PMCPA ruled that the complainant “had not established that general promotional activity, in the context of supply issues, was such that high standards had not been maintained.” However, it said ...

The Y9S3.3 Patch for Rainbow Six Siege has arrived, bringing with it a handful of Operator balance changes, weapon updates, bug fixes, and more! This page acts as a comprehensive breakdown of the ...

Our rating: 4.8 out of 5 Starting price: Free for basic business checking services. No monthly maintenance fees or minimum balance requirements. Key features: Novo Business Checking is gaining ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s ...

Warren’s concerns here but rather focus on the language. She—and BioSpace—were wrong to state that Novo Nordisk itself is buying Catalent for $16.5 billion. As journalists, we value accuracy above all ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

Denmark unveiled an Nvidia-powered supercomputer that will be used by researchers from Novo Nordisk A/S and other Danish pharmaceutical companies as they seek novel drugs and smarter trial designs.

Novo Nordisk asked the Food and Drug Administration to prevent compounding pharmacies from making cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic.

Novo Holdings first unveiled plans to pay $16.5 billion for CDMO giant Catalent in early February. Both Catalent and Novo remain confident the transaction will close before 2024 is over.

Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which includes drugs that are too complicated to produce and could pose substantial ...